NCT00889330

Safety and Efficacy Study of a Eye Drop for Eye Allergy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Vistakon Pharmaceuticals · Industry
• Sex: All
• Age: 10 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of an anti-allergy eyedrop.

Conditions

• Allergic Conjunctivitis

Interventions

Type	Name	Description
DRUG	alcaftadine	0.25% Ophthalmic Solution, one drop in each eye at each of two visits.
DRUG	Placebo	Vehicle without active, one drop in each eye at each of two visits.

Timeline

• Start date: 2009-04-01
• Primary completion: 2009-05-01
• First posted: 2009-04-28
• Last updated: 2015-03-06
• Results posted: 2011-12-08

Locations

2 sites across 1 country: United States